STAMFORD, Conn.--(BUSINESS WIRE)--
Regulatory News:
Philip Morris International Inc. (PMI) (NYSE: PM) will host a live webcast of a fireside chat session with Jacek Olczak, Chief Executive Officer, at the 2024 Barclays Global Consumer Staples Conference at on Tuesday, September 3, 2024, at approximately 12:45 p.m. ET. An archived copy of the webcast will be available until 5:00 p.m. ET on Friday, October 4, 2024, at the same site.
The webcast will provide a live stream of the entire PMI session. The webcast may also be accessed on mobile devices by downloading PMI’s free Investor Relations Mobile App at
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested over $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products and renewal applications for these products are presently pending before the FDA. As of June 30, 2024, PMI's smoke-free products were available for sale in 90 markets, and PMI estimates that 36.5 million adults around the world use PMI's smoke-free products. Smoke-free business accounted for approximately 38% of PMI’s total first-half 2024 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit and .
View source version on businesswire.com:
